Facts and reflections on COVID-19 and anti-hypertensives drugs

Abstract

Based on some publications that associate SARS-CoV-2 infection with the use of anti-hypertensivedrug groups such as angiotensin-converting-enzyme inhibitors (e.g. enalapril) or angiotensin IIreceptor blockers (e.g. losartan), many patients from South America, Central America or Spain,have stopped or intend to interrupt their treatments with these drugs. Hence, it may exist ominousconsequences due to this drop out. For this reason, it is necessary to quickly warn about thissituation and the risks associated with it.